Radiation Necrosis of the Brain and HBOT

TL;DR: Radiation necrosis of the brain is late tissue injury that can develop months or years after brain radiotherapy, stereotactic radiosurgery (SRS), or proton therapy for primary brain tumours, brain metastases, or adjacent head and neck cancers. It mimics tumour recurrence on imaging, can cause headaches, seizures, neurological deficits, and cognitive decline, and has historically been difficult to treat. Corticosteroids are the usual first response; bevacizumab is now a common second-line option; surgical resection or laser interstitial thermal therapy are reserved for severe or refractory cases. Hyperbaric oxygen therapy (HBOT) is used as an adjunct in selected patients, with a long-standing but evidence-limited track record. Current systematic reviews suggest HBOT is reasonable to consider in refractory cases, though high-quality randomised trials are still lacking. This Daffodil Month, we explain what brain radiation necrosis is, what the current research shows, and what Canadian cancer patients need to know.

Estimated reading time: 11 minutes

What Is Radiation Necrosis of the Brain?

Radiation necrosis of the brain is a form of delayed radiation injury in which previously irradiated brain tissue undergoes progressive damage months to years after treatment ends. The damage is driven by a combination of microvascular injury, impaired blood-brain barrier function, chronic inflammation, free radical production, and local tissue ischaemia within the irradiated volume. Over time, these processes can produce a focus of non-viable brain tissue surrounded by oedema, which behaves clinically and radiographically like a brain lesion.

Brain radiation necrosis typically appears 6 months to 3 years after radiotherapy, although cases have been reported up to a decade later. It is most commonly recognised today as a complication of stereotactic radiosurgery (SRS) for brain metastases, but it also occurs after whole-brain radiotherapy (WBRT), fractionated radiotherapy for glioma, and radiotherapy for head and neck cancers whose fields included brain tissue. The rise of SRS and hypofractionated treatment of brain metastases has brought radiation necrosis back into the clinical spotlight in neuro-oncology centres across Canada.

During Daffodil Month, the Canadian Cancer Society highlights cancer survivorship issues that persist long after active treatment ends. Radiation necrosis of the brain is one of the most difficult late effects in this category: it can progressively impair cognition, balance, speech, memory, and independence in a patient whose original cancer was otherwise successfully treated.

Who Is at Risk?

Any patient who receives therapeutic radiation to brain tissue is potentially at risk, but certain treatment patterns carry higher rates:

Treatment	Typical cancer	Approximate rate of symptomatic necrosis
Stereotactic radiosurgery (SRS) for brain metastases	Lung, breast, melanoma, renal cell, colorectal metastases	Roughly 5% to 25%, rising with larger lesion size, prior WBRT, and repeat SRS
Fractionated radiotherapy for high-grade glioma	Glioblastoma, anaplastic astrocytoma	Roughly 3% to 24%, depending on dose, concurrent temozolomide, and field size
Whole-brain radiotherapy (WBRT)	Diffuse brain metastases, leptomeningeal disease	Lower per-patient incidence but broader cognitive injury profile
Proton or photon therapy for skull-base and paediatric brain tumours	Chordoma, medulloblastoma, ependymoma, craniopharyngioma	Variable; location-dependent
Radiotherapy for nasopharyngeal and adjacent head and neck cancers	Nasopharyngeal carcinoma, skull-base tumours	Reported temporal lobe necrosis in a minority of long-term survivors

Well-established risk factors include higher biological effective dose, larger treated volume, repeat or re-irradiation, concurrent chemotherapy (particularly bevacizumab-containing regimens before re-irradiation), underlying vascular disease, and longer post-treatment survival. Patients with excellent systemic cancer control who live longer after brain radiation are, paradoxically, more likely to live long enough to experience late radiation injury.

How Is It Diagnosed?

One of the core clinical challenges in neuro-oncology is that radiation necrosis and tumour recurrence can look almost identical on conventional contrast-enhanced MRI. Both produce an enhancing lesion, perilesional oedema, and local mass effect. The clinical consequences of getting this wrong are significant: treating necrosis as tumour can lead to unnecessary salvage therapy, while treating recurrence as necrosis can delay cancer-directed treatment.

Canadian neuro-oncology centres typically combine several approaches to distinguish the two:

Serial MRI with attention to lesion trajectory over weeks to months
Perfusion MRI measuring relative cerebral blood volume (rCBV), which is typically lower in necrosis and higher in recurrent tumour
MR spectroscopy evaluating choline, creatine, and N-acetylaspartate ratios
Amino acid PET imaging (18F-FET or 11C-methionine) where available, useful in ambiguous cases
Biopsy or surgical resection, reserved for cases where imaging is not conclusive and treatment depends on the answer

Because imaging alone is often not definitive, many patients with suspected necrosis are treated empirically while the clinical and radiographic course is observed over time.

Why Is It So Hard to Treat?

Treatment options for symptomatic brain radiation necrosis have grown in recent decades, but none is curative and all carry trade-offs. The standard tiered approach in Canadian practice is broadly:

Observation and symptom management for mild, stable disease
Corticosteroids (typically dexamethasone) for symptomatic oedema, accepting the significant longer-term side effect burden of chronic steroids
Bevacizumab, a VEGF inhibitor, which has multiple prospective studies supporting reduced oedema and clinical improvement, although response is not universal and relapses are common when it is stopped
Laser interstitial thermal therapy (LITT) for selected focal lesions, available at a small number of Canadian centres
Surgical resection for refractory, accessible lesions with significant mass effect
Adjunctive therapies including hyperbaric oxygen therapy, pentoxifylline and vitamin E, and anticoagulation in selected cases

The difficulty is that the underlying pathology is a mixture of injured microvasculature, chronic inflammation, and an ischaemic wound inside the brain. No single drug restores all three. This is the same biological rationale that has kept hyperbaric oxygen therapy in the conversation for decades.

How Might HBOT Help?

Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen at pressures typically between 2.0 and 2.4 atmospheres absolute (ATA). At this pressure, dissolved plasma oxygen increases roughly 14 to 18 times above baseline, which enables oxygen to reach tissues with compromised microcirculation. The biological effects with direct relevance to brain radiation necrosis include:

Angiogenesis: a sustained course of HBOT (typically 30 to 40 sessions) promotes the growth of new capillaries in chronically ischaemic irradiated tissue
Improved perfusion of the peri-necrotic region, where the blood-brain barrier has been damaged and microvascular density is reduced
Reduced inflammation through down-regulation of inflammatory signalling and oxidative stress pathways
Mobilisation of progenitor cells from bone marrow into circulation
Reduction of oedema through restoration of vascular integrity and anti-inflammatory effects

These are the same mechanisms that make HBOT a standard adjunct for soft tissue radiation necrosis in the head and neck, bladder, and bowel. The question for brain radiation necrosis specifically is whether the mechanisms translate into measurable clinical benefit, given that the central nervous system has its own unique biology.

What Does the Research Show?

Evidence for HBOT in brain radiation necrosis comes from a mix of retrospective case series, small prospective studies, systematic reviews, and pre-clinical laboratory work. High-quality randomised controlled trials specific to brain necrosis remain limited.

Clinical Case Series: HBOT for Brain Radiation Necrosis

A clinical series on hyperbaric oxygen for radiation necrosis of the brain reported outcomes in patients treated with HBOT for biopsy-supported or imaging-supported brain necrosis after SRS, WBRT, or fractionated radiotherapy. A meaningful proportion of patients showed clinical improvement, reduction in corticosteroid requirement, and stabilisation or regression of the lesion on follow-up MRI. Not all patients responded, and the authors emphasised that HBOT was part of a multimodal approach, typically used after or alongside steroids and in selected cases bevacizumab.

Systematic Review and ISRS Recommendations

The International Stereotactic Radiosurgery Society (ISRS) commissioned a systematic review informing the management of symptomatic brain radiation necrosis after stereotactic radiosurgery. The review evaluated the overall evidence base for corticosteroids, bevacizumab, surgery, LITT, and HBOT. HBOT is identified as a reasonable adjunct in refractory or relapsed cases, particularly where steroid dependence or bevacizumab failure is an issue, while noting that supporting evidence is largely observational and that consensus recommendations remain based on lower-level data. The ISRS guidance is an important reference point because it is the most recent specialty-society synthesis covering the topic.

Interventions Review for Radionecrosis After Radiotherapy or Radiosurgery

An earlier systematic review evaluating interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery looked across the full therapeutic landscape, including corticosteroids, bevacizumab, surgery, LITT, anticoagulation, pentoxifylline and vitamin E, and HBOT. The authors concluded that bevacizumab has the strongest prospective evidence, that surgery and LITT have clear roles for refractory focal disease, and that HBOT has a supporting role with generally favourable observational outcomes but limited randomised evidence. The same message recurs across the radiation-necrosis literature: treatment decisions are individualised, and no single modality is dominant.

Pre-Clinical Evidence: HBOT and Radiation-Induced Cognitive Deficits

Beyond necrosis itself, there is growing interest in whether HBOT can help with the broader cognitive dysfunction that follows cranial radiotherapy. A 2025 pre-clinical study showed that HBOT attenuated brain radiation-induced cognitive deficits in rats. The study documented improved memory and learning performance, with associated changes in neuroinflammatory markers and hippocampal cell survival. Pre-clinical findings are not a substitute for human evidence, but they support the broader rationale that oxygen-based therapy can modify several of the biological processes driving post-radiotherapy brain injury.

Summary of the Evidence Base

Clinical case series and small cohort studies: generally supportive, with meaningful response rates in refractory disease
Specialty-society reviews (ISRS): HBOT positioned as a reasonable adjunct, not first-line
Pre-clinical evidence: consistent across multiple models for reduced neuroinflammation, improved vascular recovery, and preserved cognition
Randomised controlled trials specific to brain necrosis: limited; the field is still dominated by retrospective and single-centre data

In short, HBOT is not first-line for brain radiation necrosis anywhere in Canadian practice, but it is a defensible adjunct in refractory cases, supported by observational evidence, specialty-society guidance, and a plausible biological mechanism.

What Canadian Patients Need to Know

Soft tissue and bone radiation necrosis are on Health Canada’s 14 recognised conditions for hyperbaric oxygen therapy. Brain radiation necrosis sits in a grey area: symptomatic brain necrosis is often pathophysiologically similar to soft tissue radiation necrosis and is treated under the same general radiation-injury umbrella at many Canadian hyperbaric programmes, but specific coverage depends on the indication and the wording used on the referral, the treating centre’s policies, and the provincial plan.

Practical points for Canadian patients exploring HBOT for brain radiation necrosis:

Start with your treating oncology team: neuro-oncology, radiation oncology, and neurosurgery should all be involved in any decision about HBOT for brain necrosis
Coverage: hospital-based hyperbaric programmes may bill the provincial plan when treatment is framed under the radiation-necrosis indication and an appropriate referral is in place. Eligibility varies by province and by centre, so confirm with the treating facility before assuming coverage. See the HBOT coverage across Canada guide for a province-by-province summary
Typical protocol: roughly 30 to 40 daily sessions at 2.0 to 2.4 ATA, with session length around 90 minutes. Protocols are usually set by the treating hyperbaric medicine physician based on lesion location, size, and clinical status
Private option: if a hospital-based programme is not available or has long wait times, a condition not covered by the provincial plan is typically self-funded at a private clinic, with per-session fees in Canada generally ranging from $150 to $350 depending on chamber type
Drug interactions: bevacizumab and HBOT are not mutually exclusive and can be used sequentially or in combination under oncology supervision. Steroid taper is often easier once HBOT is underway
Monitoring: response is typically judged by symptom trajectory, steroid dose, and serial MRI every 2 to 3 months, not session by session

The Canada Hyperbarics facility directory lists hospital-based and private hyperbaric programmes across the country, including several centres with experience in late radiation-injury indications. Patients should ask any potential centre about their experience with brain radiation necrosis specifically, including how many such patients they have treated and how they coordinate with neuro-oncology.

Is HBOT Safe After Brain Radiation?

HBOT is generally well tolerated in brain radiation necrosis patients. Multiple safety reviews have concluded that HBOT does not promote tumour growth or recurrence. Because HBOT is an established treatment for late radiation tissue injury, it has accumulated a long safety record specifically in cancer-survivor populations, including patients with a history of malignancy in the treated field.

The typical side effects are mild and usually transient: middle-ear barotrauma from pressure changes, temporary myopia that resolves after treatment completes, confinement anxiety, and rare episodes of oxygen toxicity. Patients with a history of seizures related to radiation necrosis remain on their usual anti-epileptic regimen throughout the course; seizure activity during HBOT itself is uncommon but protocols are in place at every accredited centre.

Patients with active or poorly controlled malignancy, recent ocular surgery, severe COPD with bullous disease, or uncontrolled pneumothorax require careful pre-treatment screening. A hyperbaric medicine physician assesses suitability for every patient as part of the intake process.

Frequently Asked Questions

How soon after brain radiotherapy could I start HBOT for suspected necrosis?

Timing depends on diagnosis and symptoms, not on a fixed interval. Radiation necrosis typically appears 6 months to 3 years after treatment, and HBOT is generally considered when symptoms persist, when steroid requirements are high, or when bevacizumab response is inadequate. Decisions are made by the treating neuro-oncology team in consultation with a hyperbaric medicine physician.

Will HBOT interfere with bevacizumab or steroids?

No major interactions are expected. HBOT is often used alongside or sequentially with bevacizumab and steroids. Many patients are able to taper steroids more easily once HBOT is underway, though this varies by individual. Any dose adjustments should be made by the prescribing oncologist.

How many HBOT sessions are typically used for brain radiation necrosis?

Protocols vary by centre, but most published series use approximately 30 to 40 daily sessions at 2.0 to 2.4 ATA, with session length around 90 minutes. A shorter test course is not typical; responses usually emerge over weeks, not days.

Is HBOT covered by my provincial health plan for brain radiation necrosis?

Coverage for HBOT under the radiation-injury indication is available at hospital-based programmes in several provinces for eligible patients. Confirm with the specific treating centre whether brain radiation necrosis is covered under their radiation-injury indication and what referral pathway applies. Private self-pay is the alternative if hospital access is not available.

Does HBOT reverse radiation damage that has already occurred?

HBOT does not reverse tissue that is already necrotic. What it can do is improve perfusion in the surrounding peri-necrotic area, reduce oedema, promote angiogenesis, and in selected patients reduce symptoms and steroid dependence. Realistic goals are stabilisation and symptom improvement, not regeneration of destroyed brain tissue.

Key Takeaway

Radiation necrosis of the brain is a late, sometimes progressive complication of cranial radiotherapy and radiosurgery that can develop months to years after successful cancer treatment. Standard first-line options are observation, corticosteroids, and bevacizumab, with surgery or laser interstitial thermal therapy for refractory focal disease. Hyperbaric oxygen therapy is a reasonable adjunct in selected, refractory cases, supported by clinical case series, specialty-society reviews, and pre-clinical evidence of improved vascular recovery and reduced neuroinflammation. Patients in Canada should pursue HBOT for brain radiation necrosis only within a coordinated plan involving their neuro-oncology team and an experienced hyperbaric medicine physician. Canada Hyperbarics is an independent educational resource; patients should verify coverage and protocols directly with the treating centre.

References

This content is for informational purposes only and does not constitute medical advice. Hyperbaric oxygen therapy for brain radiation necrosis should only be considered within a coordinated plan involving the treating neuro-oncology, radiation oncology, and hyperbaric medicine teams. Coverage and access vary by province and by treating centre. Canada Hyperbarics is an independent educational resource and is not affiliated with any specific clinic or manufacturer. Patients should consult their own clinicians before pursuing any HBOT-based treatment plan.

Back to All Articles

Radiation Necrosis of the Brain and HBOT: What the Research Shows